United States Endobronchial Ultrasound Biopsy Market Size and Forecast 2025–2033

United States Endobronchial Ultrasound Biopsy Market Overview

The United States Endobronchial Ultrasound (EBUS) Biopsy Market is poised for steady growth over the next decade as healthcare providers increasingly prioritize minimally invasive diagnostic solutions. According to Renub Research, the market is expected to expand from US$ 246.82 billion in 2024 to US$ 356.2 billion by 2033, registering a compound annual growth rate (CAGR) of 4.16% from 2025 to 2033.

Download Free Sample Report

This growth trajectory reflects the mounting burden of lung-related diseases, particularly lung cancer and chronic respiratory disorders, alongside rapid advancements in imaging-guided biopsy technologies. As hospitals and specialty clinics seek safer, faster, and more accurate diagnostic procedures, EBUS biopsy has emerged as a cornerstone of modern pulmonary diagnostics in the United States.

United States Endobronchial Ultrasound Biopsy Industry Outlook

Endobronchial ultrasound biopsy has become a critical diagnostic tool for pulmonologists and oncologists due to its ability to obtain tissue samples from the lungs and mediastinal lymph nodes without the need for invasive surgery. Unlike traditional surgical biopsies, which carry higher risks and extended recovery times, EBUS biopsy offers real-time imaging, improved accuracy, and significantly reduced patient discomfort.

The growing demand for precision medicine and early disease detection has further strengthened the role of EBUS biopsy in clinical practice. Lung cancer remains one of the most serious health challenges in the United States, and accurate staging is essential for selecting appropriate treatment pathways. EBUS biopsy enables clinicians to stage lung cancer effectively while minimizing procedural risks, making it a preferred option for both patients and healthcare providers.

Beyond oncology, EBUS biopsy plays a vital role in diagnosing chronic obstructive pulmonary disease (COPD), tuberculosis, sarcoidosis, and other respiratory conditions. As awareness of minimally invasive diagnostics increases, adoption rates for EBUS biopsy continue to rise across diverse healthcare settings.

Growing Burden of Respiratory Diseases Fueling Demand

The increasing prevalence of respiratory disorders is a major driver of the U.S. EBUS biopsy market. According to the American Lung Association, 11.7 million adults in the United States were diagnosed with COPD in 2022, representing approximately 4.6% of the adult population. This significant patient base underscores the need for accurate and efficient diagnostic tools.

Similarly, lung and bronchus cancer continues to exert a heavy clinical and economic burden. The American Cancer Society’s Cancer Statistics 2024 estimates that 234,500 new cases of lung and bronchus cancer will be diagnosed in the U.S. in 2024 alone. Early detection and precise staging are critical for improving survival outcomes, and EBUS biopsy has become central to achieving these goals.

The rising incidence of respiratory infections and inflammatory lung diseases further supports market expansion. As clinicians increasingly seek diagnostic methods that combine accuracy with patient safety, EBUS biopsy stands out as an indispensable solution.

Strong R&D Investment Supporting Market Growth

The United States’ robust investment in respiratory disease research continues to stimulate innovation in EBUS biopsy technologies. According to the Condition and Disease Categories (RCDC) May 2024 update, the country allocated USD 148 million for COPD research, USD 595 million for tuberculosis, and USD 504 million for lung cancer in 2023.

These investments are accelerating the development of advanced ultrasound processors, enhanced biopsy needles, and improved imaging software. As next-generation EBUS systems enter the market, healthcare providers gain access to tools that deliver higher diagnostic accuracy, reduced procedure times, and improved patient outcomes—further reinforcing market growth during the forecast period.

Key Factors Driving the United States EBUS Biopsy Market

Rising Preference for Minimally Invasive Diagnostics

The shift toward minimally invasive healthcare solutions is a defining trend in the U.S. medical landscape. Patients increasingly demand procedures that reduce pain, shorten recovery times, and lower complication risks. EBUS biopsy aligns seamlessly with these expectations by offering a safe, outpatient-friendly alternative to surgical biopsy methods such as mediastinoscopy.

From a health system perspective, minimally invasive diagnostics also help reduce hospital stays and overall treatment costs. These economic and clinical benefits have positioned EBUS biopsy as a standard diagnostic approach in pulmonology and oncology departments nationwide.

Technological Advancements in Imaging and Biopsy Tools

Continuous technological innovation has significantly enhanced the performance of EBUS biopsy systems. Modern ultrasound probes provide clearer visualization of lymph nodes, while improved biopsy needles enable precise tissue sampling from difficult-to-reach areas.

The integration of digital technologies—including AI-assisted image interpretation and cloud-based diagnostic platforms—has further streamlined workflows and improved diagnostic confidence. As these advancements become more widespread, EBUS biopsy procedures are becoming faster, safer, and more reliable, encouraging broader adoption across healthcare facilities.

Expanding Role in Lung Cancer Diagnosis and Staging

EBUS biopsy has become indispensable in lung cancer management due to its ability to support accurate staging with minimal invasiveness. Precise staging is essential for determining whether patients require surgery, chemotherapy, radiation therapy, or targeted treatments.

As lung cancer incidence continues to rise, the demand for accurate, real-time diagnostic tools will remain strong. EBUS biopsy’s ability to deliver actionable insights with minimal patient risk ensures its continued relevance in oncology care pathways.

Challenges Facing the United States EBUS Biopsy Market

High Cost of Equipment and Procedures

Despite its clinical advantages, EBUS biopsy systems require substantial upfront investment. Advanced ultrasound processors, specialized scopes, and disposable biopsy needles contribute to high equipment and maintenance costs. For smaller hospitals and outpatient facilities, these expenses may limit adoption.

While reimbursement policies generally support minimally invasive diagnostics, variations in coverage and patient out-of-pocket costs can also create access barriers. Addressing affordability without compromising technological innovation remains a key challenge for manufacturers and providers.

Need for Skilled and Trained Operators

EBUS biopsy is a technically demanding procedure that requires specialized training and experience. A shortage of skilled pulmonologists and endoscopists—particularly in rural and underserved regions—can restrict procedural availability.

Although training programs and certification pathways are expanding, the learning curve remains steep. Ensuring widespread access to skilled operators is essential for maximizing the market’s growth potential and maintaining high standards of patient safety.

United States Endobronchial Ultrasound Biopsy Market by State

California

California leads the U.S. EBUS biopsy market due to its advanced healthcare infrastructure, strong research ecosystem, and large patient population. The state’s academic medical centers and innovation-driven healthcare providers actively adopt cutting-edge diagnostic technologies, making California a critical growth hub.

Texas

Texas is emerging as a major market driven by its rapidly expanding healthcare sector and rising burden of respiratory diseases. Large metropolitan areas such as Houston and Dallas house world-class cancer centers that increasingly rely on EBUS biopsy for lung cancer diagnosis and staging.

New York

New York’s concentration of premier hospitals, specialty clinics, and research institutions supports robust demand for EBUS biopsy. Strong academic-industry collaborations and patient-centered care models further enhance adoption across the state.

Florida

Florida’s aging population and high prevalence of respiratory conditions make it an important growth market. Increasing adoption of minimally invasive diagnostics across hospitals and specialty clinics positions Florida as a key contributor to national market expansion.

Market Segmentation Overview

By Product

EBUS Scopes

EBUS Needles

Ultrasound Processors & Imaging Systems

Accessories

By Application

Cancer Diagnostics

Infection Diagnostics

Others

By End Use

Hospitals

Ambulatory Surgical Centers (ASCs)

Specialty Clinics

By State

California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, New Jersey, Washington, North Carolina, Massachusetts, Virginia, Michigan, Maryland, Colorado, Tennessee, Indiana, Arizona, Minnesota, Wisconsin, Missouri, Connecticut, South Carolina, Oregon, Louisiana, Alabama, Kentucky, and the Rest of the United States

Competitive Landscape

The U.S. EBUS biopsy market is highly competitive, with leading medical device manufacturers focusing on innovation, strategic partnerships, and portfolio expansion. Key players include:

GE Healthcare

Siemens Healthcare Private Limited

Koninklijke Philips N.V.

Boston Scientific Corporation

Olympus Corporation

Cook Group Incorporated

FUJIFILM Holdings Corporation

Medi-Globe Technologies GmbH

These companies continue to invest in R&D, product enhancements, and clinician training programs to strengthen their competitive positions.

Final Thoughts

The United States Endobronchial Ultrasound Biopsy Market is on a steady growth path, driven by rising respiratory disease prevalence, expanding demand for minimally invasive diagnostics, and continuous technological innovation. With the market projected to reach US$ 356.2 billion by 2033, EBUS biopsy is set to remain a cornerstone of pulmonary and oncology diagnostics in the U.S.

While challenges related to cost and workforce training persist, strong research investment, supportive reimbursement frameworks, and growing awareness of patient-friendly diagnostic solutions are expected to sustain long-term growth. As healthcare systems increasingly emphasize precision, safety, and efficiency, endobronchial ultrasound biopsy will continue to play a vital role in shaping the future of respiratory disease diagnosis and management in the United States.